News
Exelixis (EXEL) stock wins a Buy at Goldman Sachs based on potential of its lead asset, zanzalintinib, ahead of a patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback